Stock in Tylenol’s parent company rallies after Trump’s unproven claims
PositiveFinancial Markets

Kenvue, the parent company of Tylenol, experienced a notable increase in its stock price following unverified claims made by former President Donald Trump regarding the medication. This rally in stock price highlights the significant impact that public figures can have on market perceptions, even when the claims are not substantiated. Investors may see this as a sign of resilience for Kenvue amidst controversy.
— Curated by the World Pulse Now AI Editorial System